Anxiety and depression in adults with cystic fibrosis: a comparison between patients and the general population in Sweden and three other European countries

BMC Pulmonary Medicine

Bo Melin³  Lena Hjelte¹  Agneta Bergsten-Brucefors²  Kimmo Sorjonen³  Lena Backström-Eriksson² 

[1] Department of Clinical Science, Intervention and Technology, Division of Pediatrics, Karolinska Institutet, Stockholm, S-141 86, Sweden;Karolinska University Hospital, Stockholm CF-center, Stockholm S-141 86, Sweden;Department of Clinical Neuroscience, Division of Psychology, Karolinska Institutet, Nobels väg 9, Solna, S-171 65, Sweden

关键词: Psychology;    Psychiatry;    HADS;    Depression;    Anxiety;    CF;    Cystic fibrosis;   

Others  :  1229491
DOI  :  10.1186/s12890-015-0117-9

 received in 2015-04-22, accepted in 2015-10-05,  发布年份 2015

【 摘 要 】

Background

Cystic fibrosis (CF) is the most common autosomal recessive life-shortening disease among Caucasians. Studies exploring the prevalence of anxiety and depression in adult CF patients are few, show inconsistent findings and rarely include comparisons with general populations. Prevalence and degree of anxiety and depression were investigated in adult CF patients in Sweden, Belgium, Germany and the UK, and compared to corresponding general population data.

Methods

Adult non-transplanted CF patients from the three largest CF-centres (out of four) in Sweden (N = 129; Age range 18–70 years; 50 % women) completed the Hospital Anxiety and Depression Scale (HADS). Studies using HADS in adult CF populations in the UK, Germany, and Belgium were included, as well as HADS normative data from the corresponding general populations.

Results

No elevated risk for anxiety and depression was found among the CF patients. However, a Country x Group interaction effect emerged; CF patients experienced a higher degree of anxiety than the general population in Sweden, but not in the other countries, though this finding did not remain significant in a logistic regression analysis. In Sweden the effect was limited to women. A Country x Group interaction effect was also found for Depression; CF patients experienced lower degree of depression than the general population in Sweden, Germany and the UK, but not in Belgium/Netherlands.

Conclusions

Contrary to earlier outcomes, the present results do not indicate any general elevated risk for anxiety and depression among CF patients. Anxiety was slightly higher in the Swedish CF population, compared to the general population; this finding was not seen in the other countries. Depression among CF patients was lower than or similar to that in the general populations in the studied countries.

【 授权许可】

   
2015 Backström-Eriksson et al.

【 参考文献 】

• [1]FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr. 1993; 122(1):1-9.
• [2]Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med. 2006; 173(5):475-82.
• [3]Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cystic Fibros. 2009; 8(2):91-6.
• [4]Brenes GA. Anxiety and chronic obstructive pulmonary disease: prevalence, impact, and treatment. Psychosom Med. 2003; 65(6):963-70.
• [5]Singer HK, Ruchinskas RA, Riley KC, Broshek DK, Barth JT. The psychological impact of end-stage lung disease. Chest. 2001; 120(4):1246-52.
• [6]Fan VS, Meek PM. Anxiety, depression, and cognitive impairment in patients with chronic respiratory disease. Clin Chest Med. 2014; 35(2):399-409.
• [7]Cruz I, Marciel KK, Quittner AL, Schechter MS. Anxiety and depression in cystic fibrosis. Semin Respir Crit Care Med. 2009; 30(5):569-78.
• [8]Quittner AL, Barker DH, Snell C, Grimley ME, Marciel K, Cruz I. Prevalence and impact of depression in cystic fibrosis. Curr Opin Pulm Med. 2008; 14(6):582-8.
• [9]Quittner AL, Goldbeck L, Abbott J, Duff A, Lambrecht P, Sole A et al. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. Thorax. 2014. doi:10.1136/thoraxjnl-2014-205983
• [10]Havermans T, Colpaert K, Dupont LJ. Quality of life in patients with Cystic Fibrosis: association with anxiety and depression. J Cystic Fibros. 2008; 7(6):581-4.
• [11]Duff AJ, Abbott J, Cowperthwaite C, Sumner C, Hurley MA, Quittner A et al. Depression and anxiety in adolescents and adults with cystic fibrosis in the UK: A cross-sectional study. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 2014. doi:10.1016/j.jcf.2014.02.010
• [12]Bergsten Brucefors A, Hjelte L, Hochwälder J. Mental health and sense of coherence among Swedish adults with cystic fibrosis. Scand J Caring Sci. 2011; 25(2):365-72.
• [13]Anderson DL, Flume PA, Hardy KK. Psychological functioning of adults with cystic fibrosis. Chest. 2001; 119(4):1079-84.
• [14]Goldbeck L, Besier T, Hinz A, Singer S, Quittner AL, Group T. Prevalence of symptoms of anxiety and depression in German patients with cystic fibrosis. Chest. 2010; 138(4):929-36.
• [15]Yohannes AM, Willgoss TG, Fatoye FA, Dip MD, Webb K. Relationship between anxiety, depression, and quality of life in adult patients with cystic fibrosis. Respir Care. 2012; 57(4):550-6.
• [16]Riekert KA, Bartlett SJ, Boyle MP, Krishnan JA, Rand CS. The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis. Chest. 2007; 132(1):231-7.
• [17]Lisspers J, Nygren A, Söderman E. Hospital Anxiety and Depression Scale (HAD): some psychometric data for a Swedish sample. Acta Psychiatr Scand. 1997; 96(4):281-6.
• [18]Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67(6):361-70.
• [19]Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002; 52(2):69-77.
• [20]Crawford JR, Henry JD, Crombie C, Taylor EP. Normative data for the HADS from a large non-clinical sample. Br J Clin Psychol. 2001; 40(Pt 4):429-34.
• [21]Jörngården A, Wettergen L, von Essen L. Measuring health-related quality of life in adolescents and young adults: Swedish normative data for the SF-36 and the HADS, and the influence of age, gender, and method of administration. Health Qual Life Outcomes. 2006; 4:91. BioMed Central Full Text
• [22]Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med. 1997; 27(2):363-70.
• [23]Hinz A, Brähler E. Normative values for the hospital anxiety and depression scale (HADS) in the general German population. J Psychosom Res. 2011; 71(2):74-8.
• [24]Stordal E, Bjartveit Kruger M, Dahl NH, Kruger O, Mykletun A, Dahl AA. Depression in relation to age and gender in the general population: the Nord-Trondelag Health Study (HUNT). Acta Psychiatr Scand. 2001; 104(3):210-6.
• [25]Modi AC, Driscoll KA, Montag-Leifling K, Acton JD. Screening for symptoms of depression and anxiety in adolescents and young adults with cystic fibrosis. Pediatr Pulmonol. 2011; 46(2):153-9.
• [26]Dennersten U, Lannefors L, Höglund P, Hellberg K, Johansson H, Lagerkvist AL et al.. Lung function in the aging Swedish cystic fibrosis population. Respir Med. 2009; 103(7):1076-82.
• [27]Lannefors L, Lindgren A. Demographic transition of the Swedish cystic fibrosis community--results of modern care. Respir Med. 2002; 96(9):681-5.
• [28]ECFSPR Annual Report 2010, Zolin A, McKone EF, van Rens J et al.,2014 Available from: https://www.ecfs.eu/projects/ecfs-patient-registry/annual-reports. Accessed 15 April 2015.
• [29]Kerem E, Webb AK. European cystic fibrosis society standards of care: A road map to improve CF outcome. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 2014. doi:10.1016/j.jcf.2014.05.003
• [30]Strandvik B, Hjelte L, Widen B. Home intravenous antibiotic treatment in cystic fibrosis. Scand J Gastroenterol Suppl. 1988; 143:119-20.
• [31]Strandvik B, Hjelte L, Malmborg AS, Widen B. Home intravenous antibiotic treatment of patients with cystic fibrosis. Acta Paediatr. 1992; 81(4):340-4.
• [32]Latchford G, Duff AJ. Screening for depression in a single CF centre. J Cystic Fibros. 2013; 12(6):794-6.
• [33]Mehta G, Macek M, Jr., Mehta A, European Registry Working G. Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 2010;9 Suppl 2:S5-S21. doi:10.1016/j.jcf.2010.08.002.
• [34]McCormick J, Mehta G, Olesen HV, Viviani L, Macek M, Mehta A et al.. Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet. 2010; 375(9719):1007-13.
• [35]Castellani C, Conway S, Smyth AR, Stern M, Stuart EJ. Standards of care for cystic fibrosis ten years later. J Cystic Fibros. 2014; 13 Suppl 1:S1-2.
• [36]Smith BA, Modi AC, Quittner AL, Wood BL. Depressive symptoms in children with cystic fibrosis and parents and its effects on adherence to airway clearance. Pediatr Pulmonol. 2010; 45(8):756-63.
• [37]DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000; 160(14):2101-7.
• [38]Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci. 2011; 13(1):7-23.